Please use this identifier to cite or link to this item: http://hdl.handle.net/11513/136
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYeşilova, Yavuz-
dc.contributor.authorÖzbilgin, Ahmet-
dc.contributor.authorTuran, Enver-
dc.contributor.authorSürücü, Hacer Altın-
dc.contributor.authorAksoy, Mustafa-
dc.date.accessioned2019-06-10T13:20:10Z-
dc.date.available2019-06-10T13:20:10Z-
dc.date.issued2014-
dc.identifier.otherDOI: 10.5152/tpd.2014.3829-
dc.identifier.urihttp://hdl.handle.net/11513/136-
dc.description.abstractClinical exacerbations were found in the patient being monitored in the dermatology clinic, 3 days after the start of systemic sodium stibogluconate treatment for cutaneous leishmaniasis (CL). The patient was the 5-year-old daughter of the first patient, who also had facial CL lesion, and the clinical exacerbation was seen on the 3rd day of treatment (systemic sodium stibogluconate) (Figure 1). This treatment was continued in both patients with the addition of 0.5 mg/kg prednisolone for 3 days. Rapid clinical recovery was shown in both patients with systemic corticosteroid (Figures 1d and 2d).en_US
dc.language.isoenen_US
dc.publisherTurkiye Parazitol Dergisien_US
dc.titleClinical Exacerbation Developing During Treatment of Cutaneous Leishmaniasis: An Id Reaction?en_US
dc.title.alternativeKutanöz Leishmaniasis Tedavisi Sırasında Oluşan Klinik Alevlenmeler: İd Reaksiyonu mu?en_US
dc.typeOtheren_US
Appears in Collections:Dahili Tıp Bilimleri Bölümü

Files in This Item:
File Description SizeFormat 
1. Clinical Exacerbation Developing During Treatment of Cutaneous.pdf95.93 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.